Valeritas
Valeritas is a public medical technology company that develops and commercializes V-Go, a non-electronic disposable wearable insulin delivery device providing basal-bolus therapy for adults with Type 2 diabetes in the US, EU and select international markets via pharmaceutical wholesalers and regional distributors.
- Company typePublic
- Founded2006
- HeadquartersBridgewater, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Valeritas does
Valeritas is a commercial-stage medical technology company headquartered in Bridgewater, New Jersey, with manufacturing and R&D operations in Shrewsbury, Massachusetts. The company develops and commercializes the V-Go Disposable Insulin Delivery Device, a wearable, fully disposable, non-electronic basal-bolus insulin system worn for 24-hour cycles that delivers a preset continuous basal rate (20, 30 or 40 units per day) plus on-demand bolus dosing in 2-unit increments. V-Go received FDA 510(k) clearance and CE marking, and was launched commercially in the United States in 2012; it is sold through authorized pharmaceutical distributors including AmerisourceBergen, Cardinal Health and McKesson, with regional partners in Australia, New Zealand and Italy.
Valeritas's primary customer is the adult Type 2 diabetes patient requiring insulin therapy — a population the company estimates at roughly 5.7 million people in the United States — with prescribing driven through endocrinologists, primary care physicians and diabetes educators. The company operates a sales-led, distributor-mediated hardware-sales model, selling single-use devices through wholesalers to healthcare providers. Its broader technology portfolio includes the h-Patch subcutaneous delivery platform and the next-generation V-Go PreFill (prefilled cartridge) and V-Go Link (Bluetooth telemetry) variants currently in development; non-core assets including the Mini-Ject needle-free injector and Micro-Trans microneedle patch are being divested.
The company is publicly traded (formerly NASDAQ: VLRX, currently OTC Markets: VLRXQ), employs 101–250 people, and has cumulatively raised an estimated $355 million in private and structured financing from investors including Welsh Carson Anderson & Stowe, MPM Capital, Kaiser Permanente Ventures, Abingworth, Advanced Technology Ventures, ONSET Ventures, Pitango VC and CRG.
Valeritas firmographics
Firmographics- Name
- Valeritas
- Legal name
- Valeritas, Inc.
- Website
- https://valeritas.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Valeritas is a public medical technology company that develops and commercializes V-Go, a non-electronic disposable wearable insulin delivery device providing basal-bolus therapy for adults with Type 2 diabetes in the US, EU and select international markets via pharmaceutical wholesalers and regional distributors.
- Ownership category
- akta.pro rank
Valeritas industry classification
Industry- Product category
- Insulin Delivery Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)
- akta.pro secondary industry
- Insulin Pumps & Patch Pumps (HLAHAIAG)
Keywords
Where Valeritas is headquartered
LocationHeadquarters
- HQ city
- Bridgewater
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Valeritas business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- V-Go Disposable Insulin Delivery Device Sales: Valeritas generates revenue from the sale of V-Go Disposable Insulin Delivery devices. V-Go is a wearable, fully disposable device worn for 24 hours and then replaced. The company sells through authorized pharmaceutical distributors and directly to healthcare providers. Commercialized in the United States since 2012, with regulatory clearance in the US and EU.
Go-to-market motion1 record
Distribution channels9 records
Marketing channels6 records
Valeritas product offering
Product offeringCore offering
Valeritas develops, manufactures, and commercializes the V-Go Disposable Insulin Delivery Device, a wearable, fully disposable basal-bolus insulin delivery system worn for 24 hours that provides continuous preset basal insulin delivery and on-demand bolus dosing. The company also markets the h-Patch controlled-delivery technology platform for subcutaneous drug administration and the non-core Mini-Ject needle-free injection system and Micro-Trans microneedle array patch, while developing next-generation V-Go PreFill and V-Go Link variants.
Product overview
Valeritas is a commercial-stage medical technology company offering a portfolio of drug delivery products focused on improving health and simplifying life for people with Type 2 diabetes. The core product is V-Go, a wearable disposable insulin delivery device providing basal-bolus insulin therapy. The product line includes next-generation V-Go variants (PreFill with prefilled insulin cartridges and Link with Bluetooth connectivity) and the h-Patch controlled delivery platform. Non-core technologies include Mini-Ject (needle-free injection system) and Micro-Trans (microneedle array patch), which the company is seeking to divest.
Differentiator
Problem solved
Functional benefit
Brands
- V-Go: V-Go Disposable Insulin Delivery Device - a small, discreet and easy-to-use wearable insulin device for adults with Type 2 diabetes.
- h-Patch
- Mini-Ject
- Micro-Trans
Products and services
- V-Go Disposable Insulin Delivery Device A small, discreet, and easy-to-use wearable insulin delivery device that adheres to the skin every 24 hours. V-Go delivers continuous preset basal insulin (20, 30, or 40 Units per 24-hour period) and provides on-demand bolus dosing in 2 Unit increments for meals and snacks. It is FDA cleared and CE marked, and has demonstrated A1C reductions with less insulin in numerous real-world analyses for adults with Type 2 diabetes requiring insulin therapy.
- V-Go PreFill Next-generation single-use disposable V-Go variant with a prefilled insulin cartridge that snaps into the device, eliminating the patient insulin-filling process to make insulin therapy even simpler for broader HCP and patient adoption. Under development.
- V-Go Link Next-generation single-use disposable V-Go variant featuring one-way communication to smart devices (phones and tablets) via RF/Bluetooth technology, providing real-time tracking of basal and bolus dosing utilization to give patients and HCPs deeper insight into dosing habits. Under development.
- h-Patch Controlled Delivery Technology Platform A simple-to-use, fully disposable controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. It combines the user advantages of transdermal patches with the accuracy and flexibility of conventional ambulatory pumps, and can accommodate pre-filled liquid or point-of-care fill for lyophilized medications.
- Mini-Ject Needle-Free Injection System A next-generation needle-free injection system combining fully disposable pre-filled options with comfortable administration. Capable of delivering a wide range of drugs from small molecules to large proteins, fragile antibodies, and vaccines, with delivery targeted to intradermal, subcutaneous, or intramuscular tissue depending on therapeutic need. Non-core technology being divested.
- Micro-Trans Microneedle Array Patch Microneedle Array Patch technology enabling drug delivery into the dermis without limitations of drug size, structure, charge, or patient skin characteristics. Arrays penetrate only shallow layers of skin to avoid pain receptors for patient comfort. Non-core technology being divested by Valeritas.
Quantifiable outcome
- V-Go has consistently shown to lower A1Cs with less insulin in numerous real-world analyses
- +1 more outcomes
Companies that use Valeritas
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Valeritas technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Valeritas partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core.
- AmerisourceBergen CorporationcoreAmerisourceBergen Corporation is an Authorized Distributor of Record for Valeritas, Inc. This designation identifies an ongoing relationship where the distributor is authorized to distribute the full line of Valeritas products. The distribution authorization was formalized following FDA regulations issued June 9, 2006 to strengthen protections against counterfeit drugs.
- ANDA, Inc.coreANDA, Inc. is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Cardinal HealthcoreCardinal Health is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- McKesson CorporationcoreMcKesson Corporation is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- HD Smith Wholesale Drug CompanycoreHD Smith Wholesale Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Burlington Drug CompanycoreBurlington Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Dakota DrugcoreDakota Drug is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Morris & Dickson Co., LLCcoreMorris & Dickson Co., LLC is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- N.C. Mutual Wholesale Drug CompanycoreN.C. Mutual Wholesale Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Prescription Supply, Inc.corePrescription Supply, Inc. is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Rochester Drug CompanycoreRochester Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Smith Drug CompanycoreSmith Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Value Drug CompanycoreValue Drug Company is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Frank W. KerrcoreFrank W. Kerr is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Miami-Luken, InccoreMiami-Luken, Inc is an Authorized Distributor of Record for Valeritas, Inc. with ongoing relationship to distribute the full line of Valeritas products.
- Australasian Medical & Scientific (AMSL)coreAMSL is the regional distributor for Valeritas products in Australia and New Zealand. Located at 2 McCabe Place, Chatswood NSW 2067, Australia. Contact: 1300 851 056.
- NZ Scientific & Medical LtdcoreNZ Scientific & Medical Ltd is a regional distributor for Valeritas products in New Zealand. Located at Mt Wellington, Auckland 1060.
- Movi SpAcoreMovi SpA is the regional distributor for Valeritas products in Italy. Located at Via Dione Cassio 15, I - 20138, Milan, Italy.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Valeritas competitors and assessment
Company assessmentDirect peers
- Insulet Corporation: Insulet's OmniPod is a tubeless, wearable patch insulin pump for people with diabetes. It is the closest direct competitor to V-Go in the disposable/wearable insulin delivery category and targets the same patient population.
- Tandem Diabetes Care: Tandem sells the t:slim X2 insulin pump with Control-IQ AID technology and competes head-to-head with V-Go for patients seeking pump therapy. It shares the same endocrinologist and diabetes educator call points.
- CeQur: CeQur develops a wearable, disposable insulin delivery patch (PaQ) for people with Type 2 diabetes. It targets the same simple, multi-day-wear use case as V-Go, making it the most direct niche competitor in patch-meal-bolus delivery.
Broad incumbents
- Medtronic (Diabetes): Medtronic's MiniMed insulin pumps, including the 780G AID system, are a long-established incumbent in insulin delivery with integrated CGM. It competes with V-Go for endocrinologist prescriptions and payor formulary slots, especially in Type 1 and insulin-requiring Type 2 patients.
- Dexcom: Dexcom is the leading continuous glucose monitor (CGM) provider and increasingly part of integrated pump+CGM diabetes management. While not a direct pump competitor, its dominance shapes the standard of care against which V-Go is prescribed.
- Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the leading CGM used by people with diabetes globally. As CGM-AID integration becomes standard, Libre sets the monitoring benchmark against which insulin delivery devices like V-Go are evaluated.
- Roche Diabetes Care: Roche offers Accu-Chek insulin pumps and broader diabetes management products internationally. It competes with V-Go in select European markets where Roche's established payor relationships could limit V-Go adoption.
Emerging players
- Bigfoot Biomedical: Bigfoot is developing a connected insulin delivery system focused on Type 1 and insulin-requiring Type 2 diabetes. It targets the same simplification-for-the-patient value proposition that V-Go pitches, but with a CGM-integrated, smart-pen/pump hybrid.
- MannKind Corporation: MannKind commercializes Afrezza, an inhaled insulin, and is developing additional endocrine delivery technologies. While delivery modality differs, MannKind competes with Valeritas for share of voice in simplifying insulin therapy for Type 2 diabetes patients reluctant to inject.
Others
- Novo Nordisk (Diabetes Care Devices): Novo Nordisk dominates the global insulin and GLP-1 market and is investing in connected pen and patch delivery devices. As a supplier of the insulin used in V-Go and a future potential competitor in patch delivery, it is an adjacent and ecosystem-defining peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Valeritas social profiles
Digital presenceValeritas financial estimates
Financial estimateRevenue estimate
Valuation estimate
Valeritas leadership team
Management profileNumber of profiles
Profiles11 records
Valeritas funding detail
Funding detailFunding overview
Funding rounds6 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Valeritas M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Valeritas
What does Valeritas do?
Valeritas develops, manufactures, and commercializes the V-Go Disposable Insulin Delivery Device, a wearable, fully disposable basal-bolus insulin delivery system worn for 24 hours that provides continuous preset basal insulin delivery and on-demand bolus dosing. The company also markets the h-Patch controlled-delivery technology platform for subcutaneous drug administration and the non-core Mini-Ject needle-free injection system and Micro-Trans microneedle array patch, while developing next-generation V-Go PreFill and V-Go Link variants.
Is Valeritas a public or private company?
Valeritas is a public company. It is classified as public and is currently operating.
When was Valeritas founded?
Valeritas was founded in 2006. It employs 101 to 250 people.
Where is Valeritas based?
Valeritas is headquartered in Bridgewater, United States, in the North America region.
How does Valeritas make money?
One revenue line is on record: V-Go Disposable Insulin Delivery Device Sales.
Who are Valeritas's main competitors?
Direct peers on record are Insulet Corporation, Tandem Diabetes Care and CeQur. Broad incumbents are Medtronic (Diabetes), Dexcom, Abbott Diabetes Care (FreeStyle Libre) and Roche Diabetes Care. Emerging players are Bigfoot Biomedical and MannKind Corporation. Novo Nordisk (Diabetes Care Devices) is listed as an others.
Does Valeritas have an API?
No public API is recorded for Valeritas.
What industry is Valeritas in?
Valeritas's product category is Insulin Delivery Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery, with a secondary code of HLAHAIAG, Insulin Pumps & Patch Pumps. Its NAICS code is 3391 and its SIC code is 3842.